Lilly to acquire US radiopharmaceutical company POINT for $1.4bn
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
04 Oct 23
POINT has two potential candidates in late-phase development, with several others in earlier stages of development, operates a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
04 Oct 23
According to the agreement, both firms will co-fund current and future research and development expenditures with Sanofi paying…
04 Oct 23
The expanded collaboration combines Intellia’s genome editing platform with Regeneron’s proprietary antibody-targeted viral vector delivery technologies to develop…
04 Oct 23
The United Nations’ health agency will consider the SAGE’s recommendation and revise its position paper on dengue vaccines…
04 Oct 23
The collaboration aims to facilitate KateTx's initial internal portfolio of gene therapy programmes focused on muscle and heart…
04 Oct 23
The potential development program reflects PharmaEssentia’s efforts to diversify its current expertise and expand its pipeline with a…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
03 Oct 23
Baxter’s BioPharma Solutions business will be renamed Simtra BioPharma Solutions (Simtra), which will continue to same solutions and…
03 Oct 23
The drugmaker has received offer for its OTC business, and has agreed to divest its women's healthcare business,…
03 Oct 23
The approval was supported by the positive findings from the Phase 2 PHYOX 2 clinical trial and interim…
03 Oct 23
GSK’s Jemperli plus chemotherapy is now approved for patients with a tumour abnormality called mismatch repair deficient /…